University of Ioannina
Συσχέτιση της γενετικής ποικιλότητας του Col17A1 με την εκδήλωση πομφολυγώδους πεμφιγοειδούς σε ασθενείς με νευρολογικές παθήσεις
Abstract
dc:descriptionBullous pemphigoid (BP) is an autoimmune disease of the skin, characterized by the presence of subepidermal bullae, with higher predominance in the elderly. It is caused by autoantibodies against the structural components of the hemidesmosomes of the basal membrane, compromising the dermal-epidermal cohesion. Correlation between BP and neurodegenerative disorders has been reported in multiple studies. The most common neurological diseases that have been correlated to this day include dementia, multiple sclerosis, stroke, Parkinson’s disease and Alzheimer’s disease. Both the epidermis and the central nervous system have common embryologic origin from the ectoderm. Common laboratory finding among the patients suffering from both diseases is the presence of autoantibodies in the serum, mostly against the protein BP 180 (Col17). Protein BP 180 is encoded by the gene COL17A1 within the chromosome 10 (10q25.1) and its main role is as structural material of the hemidesmosomes. It can also be found as structural material within the central nervous system, as well as in other types of tissue, in which its role remains unknown. The purpose of this dissertation is the investigation of the possible correlation between the genetic variation of the gene COL17A1 with the development of bullous pemphigoid in patients with neurological disorders. The study aims to examine the hypothesis that the protein Col17 (BP 180) acts as common antigen which stimulates an immune response against the skin and the central nervous system. Genetic variation can affect the expression of the protein, and in the case of amino-acid substitution, the ability of the MHC molecules to present collagen XVII to the immune system, as well as the ability of the peripheral autoantibodies to connect with the molecule. Regarding gene COL17A1, 19 variants (SNVs) have been identified, from which only 3 result in changes within coding regions involving amino-acid substitution (rs805708, rs805722 and rs17116350). In this study, these 3 variants were genotyped in 4 groups of patients: 1. Patients with BP and neurological disorders (BPN – 61 patients), 2. Patient with BP (BP – 57 patients), 3. Patient with neurological diseases (N – 53 patients), 4. Controls (C – 60 patients). Molecular techniques were used to detect the genetic variation. Blood samples were collected from all the participants, after consent was given. From each sample, genomic DNA was isolated. Using PCR technique, the 3 segments of the gene COL17A1 containing the exons of interest were multiplied. For each exon, a specific restriction endonuclease was used in order for the sequence at the site of the variant to be identified. Statistical analysis of the results wasn’t able to reveal statistically safe conclusions regarding the hypothesis of the correlation between genetic variation of the gene COL17A1 and the development of BP in patient with neurological disorders. Most comparisons were not statistically significant. A few statistically significant correlations emerged, which could not be evaluated on their own, due to the Hardy-Weinberg disequilibrium of the control group regarding variant rs805722, as well as the predominance of this variant in the studied population. A significant finding was the predominance of the variant rs805722 of the exon 27 in the studied population. This predominance had a negative impact on the statistical analysis, leading to possible statistical bias. An equally remarkable result was the increased incidence of neurological disorders, by 1.6 times, in patients presenting the variant rs805708 in exon 10. In the main group study (BPN), 10 patients were identified with negative ELISA test for BP 180 and BP 230 autoantibodies. The serum of these patients, who were excluded from the group, was tested with immunoblotting (Western Blot) for the presence of new epitopes. Autoantibodies against numerous proteins, of different molecular weights, were found in the serum of the patients, which could not be identified though. To this day, it is not clear whether one disease precedes the other, or whether both are the result of other pathogenetic pathways and causes. Further investigation is required in order for the immunologic link between neurodegenerative disorders and bullous pemphigoid to be identified.
Degree
thesis:*- Grantor dc:publisher
- University of Ioannina
- Year dc:date
- 2023
Author and committee
dc:creator, dc:contributor.*- Authors dc:creator
-
- Meltzanidou, Parthena
- Μελτζανίδου, Παρθένα
Subjects
dc:subject × 22- Γενετική ποικιλότητα
- Πομφολυγώδες πεμφιγοειδές
- Νευρολογικές παθήσεις
- Col17A1
- rs805708
- rs805722
- rs17116350
- Genetic variation
- Bullous pemphigoid
- Neurological disorders
- Βασική Ιατρική
- Ιατρική και Επιστήμες Υγείας
- Γενετική ανθρώπου
- Κλινική Ιατρική
- Δερματολογία
- Κλινική νευρολογία
- Basic Medicine
- Medical and Health Sciences
- Human genetics
- Clinical Medicine
- Dermatology
- Clinical Neurology
Rights
- Language dc:language
- gre
Identifiers
dc:identifier.*- Identifier
- 10.12681/eadd/55071